According to an article from PMLive.com, “AstraZeneca (AZ) has teamed up with Abbott to develop a companion diagnostic for experimental asthma drug tralokinumab, currently in phase III testing.  To date there are no approved companion diagnostics for asthma therapies, according to AZ, which said the diagnostic would be able to identify patients most likely to respond to treatment with the drug.”  For more information on this new development, please visit: http://www.pmlive.com/pharma_news/az_links_with_abbott_on_personalised_asthma_diagnostic_736060